Esbriet

August 16, 2019August 16, 2019

Taking Esbriet for IPF Does Not Increase Risk of Heart Problems, Analysis Says

Esbriet, News

Taking Esbriet (pirfenidone) to manage idiopathic pulmonary fibrosis (IPF) does not increase the risk of heart problems or interfere with commonly used cardiovascular medications, an analysis found. Results of ... Read more

June 19, 2019June 21, 2019

Esbriet Helps Halt Breathlessness Symptoms in Severe IPF, Analysis of Multiple Trials Shows

Esbriet, News

Treatment with Esbriet (pirfenidone) slows the worsening of breathlessness in patients with more severe idiopathic pulmonary fibrosis (IPF), a post-hoc analysis of the ASCEND and CAPACITY trials shows. The ... Read more

April 8, 2019

Secondary Insurance Coverage Boosts Adherence to Treatment with Ofev, Esbriet, Study Finds

Esbriet, News

Although patients with idiopathic pulmonary fibrosis (IPF) who take Ofev (nintedanib) or Esbriet (pirfenidone) have similar clinical outcomes, adherence to treatment is higher among those who have secondary insurance coverage, ... Read more

March 26, 2019April 4, 2019

Esbriet Safe and Effective for Patients with Advanced Idiopathic Pulmonary Fibrosis, Trial Suggests

Esbriet, News

A post-hoc analysis of the Phase 3 RECAP trial shows that long-term treatment with Esbriet (pirfenidone) is safe and similarly effective in patients with advanced idiopathic pulmonary fibrosis (IPF) as in ... Read more

January 30, 2019February 5, 2019

Esbriet Extends Long-term Survival, Slows IPF Progression, Real-life Study Reveals

Esbriet, News

Treatment of idiopathic pulmonary fibrosis (IPF) with Esbriet (pirfenidone) increased five-year survival, and also resulted in less decline in lung function at two years, according to a real-life study ... Read more

January 23, 2019January 31, 2019

Real-world Use of Esbriet and Ofev Supports Their Safety and Tolerability, Study Says

Esbriet, News

The tolerability and safety of Ofev (nintedanib) and Esbriet (pirfenidone) treatments in a small group of patients with idiopathic pulmonary fibrosis (IPF) in South England were found to be ... Read more

January 14, 2019January 14, 2019

Esbriet Reduces Risk of IPF Progression Over One Year, Pooled Analysis Shows

Esbriet, News

One year of treatment with Genentech‘s Esbriet (pirfenidone) significantly reduced the incidence of disease progression events — including decline in lung function and physical capacity, respiratory-related hospitalizations, and death — in people ... Read more

December 7, 2018December 11, 2018

Esbriet Extends IPF Patient Survival, Real-world Study Reports

Esbriet, News

Esbriet (pirfenidone) can improve survival rates of idiopathic pulmonary fibrosis (IPF) patients by 30 percent, a real-world retrospective analysis shows. The study, “Pirfenidone improves survival in IPF: results from a ... Read more

November 6, 2018November 9, 2018

No New Safety Concerns with Esbriet, Results from Long-term PASSPORT Study Show

Esbriet, News

Results from the long-term PASSPORT clinical study are consistent with the known safety profile of Esbriet (pirfenidone), further strengthening the safety of the therapy in patients with idiopathic pulmonary fibrosis ... Read more

October 12, 2018October 17, 2018

Analysis of Phase 3 Trial Data Shows Benefits of Esbriet for More Advanced IPF Patients

Esbriet, News

Treatment with Esbriet (pirfenidone) can effectively benefit patients with idiopathic pulmonary fibrosis (IPF) who have more advanced lung function impairment, by preventing a decline in exercise capacity and worsening ... Read more

Pin It on Pinterest